From the integrated genomic data from tumor samples of 4 AT/RT patients, we narrowed down the candidate therapeutic targets to identify nucleophosmin (NPM1), a multifunctional phosphoprotein involved in ARF/p53 pathway regulation, as a novel potential therapeutic target for AT/RTs. The gene discussed is CDKN2A; the disease is neoplasm.